Form 4: Rafael Holdings Converts Debt to Equity in Cyclo Therapeutics
SEC Form 4 Filing
Rafael Holdings converted $2.5 million of debt into 3,968,254 shares of Cyclo Therapeutics common stock.
Summary
- Rafael Holdings, a significant shareholder of Cyclo Therapeutics, converted $2.5 million of a convertible promissory note into common stock.
- The conversion resulted in Rafael Holdings acquiring 3,968,254 shares of Cyclo Therapeutics common stock.
- The conversion price was $0.63 per share, based on the closing price of Cyclo Therapeutics' stock on December 20, 2024.
- Following the transaction, Rafael Holdings now beneficially owns 12,998,194 shares of Cyclo Therapeutics common stock.
Sentiment
Score: 7
Explanation: The conversion of debt to equity is generally a positive sign for the company's financial health, but it does dilute existing shareholders. The sentiment is moderately positive.
Positives
- The conversion of debt to equity strengthens Cyclo Therapeutics' balance sheet by reducing its debt obligations.
- Rafael Holdings' increased equity stake demonstrates their continued commitment to Cyclo Therapeutics.
Risks
- The conversion of debt to equity dilutes existing shareholders' ownership.
Industry Context
Debt-to-equity conversions are a common financial maneuver, especially for companies seeking to improve their balance sheets or when a major shareholder wants to increase their stake. This is a common practice in the biotech industry.
Comparison to Industry Standards
- Debt-to-equity conversions are a common practice for companies with significant debt, especially in the biotech sector where funding can be challenging.
- The conversion price of $0.63 per share is based on the market price at the time, which is a standard practice.
- Similar transactions can be seen with other biotech companies that have significant debt and major shareholders.
Stakeholder Impact
- Existing shareholders will experience a dilution of their ownership due to the issuance of new shares.
- The company's balance sheet is strengthened by the reduction of debt.
Key Dates
| Date | Description |
|---|---|
| 2024-08-21 | Date of the Convertible Promissory Note made by Cyclo Therapeutics in favor of Rafael Holdings. |
| 2024-12-20 | Date of the closing price of Cyclo Therapeutics' common stock used to determine the conversion price. |
| 2024-12-23 | Date Rafael Holdings elected to convert the debt into equity. |
| 2025-01-13 | Date of the signature of the report by William Conkling, CEO. |
Keywords
debt conversion, equity, common stock, Rafael Holdings, Cyclo Therapeutics, promissory note, shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.